Colinz Laboratories Ltd

Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported net profit of ₹0.17 crores for the quarter ended March 2026 (Q4 FY25), marking a 112.50% surge on a quarter-on-quarter basis from ₹0.08 crores in Q3 FY25. On a year-on-year basis, the company posted a modest 13.33% growth from ₹0.15 crores in Q4 FY24. However, this profit improvement comes against a backdrop of declining annual revenues and persistent operational challenges that raise questions about the sustainability of this performance.

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 27 Apr 2026. This shift reflects deteriorating technical indicators, stagnant financial trends, and weak fundamental quality, despite an attractive valuation. The stock’s recent performance and outlook suggest caution for investors amid challenging market conditions.

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 21 April 2026. This change reflects a nuanced shift in the company’s technical outlook despite persistent fundamental challenges. The upgrade is primarily driven by a stabilisation in technical indicators, while valuation and financial trends continue to present a mixed picture for investors.

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 19 Mar 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent fundamental challenges, prompting investors to reassess its near-term prospects.

Colinz Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Mar 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite a micro-cap status and an attractive valuation on price-to-book metrics, the company’s financial trends and technical signals have worsened, prompting a reassessment of its investment appeal.

Colinz Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite recent volatility in its share price and mixed returns relative to the broader market. This change reflects improved price-to-earnings and price-to-book value metrics, positioning the pharmaceutical and biotechnology firm as a potentially compelling investment within its sector.

Colinz Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from fair to attractive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, suggests a recalibration of price attractiveness amid a challenging market backdrop and evolving sector dynamics.

Colinz Laboratories Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with its recent market performance and peer comparisons, offers investors a fresh perspective on the stock’s price attractiveness amid a challenging industry backdrop.

Colinz Laboratories Ltd has recently formed a Golden Cross, a significant technical indicator where the 50-day moving average (DMA) has crossed above the 200-day moving average. This development often signals a potential bullish breakout, indicating a possible trend reversal and a shift towards long-term upward momentum for the pharmaceutical and biotechnology company.

Colinz Laboratories Ltd., a micro-cap pharmaceutical formulations manufacturer, reported a modest quarterly performance for Q3 FY26, with net profit declining 42.86% quarter-on-quarter to ₹0.08 crores from ₹0.14 crores in Q2 FY26. On a year-on-year basis, net profit increased 60.00% from ₹0.05 crores in Q3 FY25, though this comparison benefits from an exceptionally weak base quarter. With a market capitalisation of just ₹13.00 crores, the Mumbai-based company continues to struggle with scale and profitability consistency, as reflected in its current stock price of ₹46.20, down 47.91% from its 52-week high of ₹88.70.

Colinz Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 11 June 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Colinz Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and operational metrics. This development highlights shifts in the company’s quality, valuation, financial trends, and technical outlook, providing investors with a clearer understanding of its current standing within a competitive industry.

Colinz Laboratories has reached a new 52-week low of Rs. 36.11, reflecting a year-to-date decline of 32.98%. Despite recent gains over three days, the company faces challenges such as weak long-term fundamentals and low return on equity, while the broader market shows mixed performance.

Colinz Laboratories has reached a new 52-week low, reflecting a significant downturn in its stock performance. The company has underperformed its sector and experienced a notable decline over the past year, with weak financial metrics contributing to its challenges in the market.